AbbVie makes its strategic entry into the obesity therapeutics market through a $350 million upfront licensing agreement with Danish biotech Gubra for their amylin analog GUB014295.
Eli Lilly's Zepbound (tirzepatide) led to a 20.2% average weight loss, significantly outperforming Wegovy (semaglutide) at 13.7% in a 72-week clinical trial.
Novo Nordisk's CagriSema, combining semaglutide and cagrilintide, is poised to release Phase III data, potentially revolutionizing obesity treatment with significant weight loss results.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.